In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases. China, where EC is the third most common female malignancy, accounted for nearly half of the new cases in Asia.
Novotech Sponsors BIO 2023 APAC Summit and the Endpoints Panel on Forging Biotech Ties with China
Boston, MA - USA - Novotech, the leading Asia Pacific centred b
Read more